View Older Stories
-
Form SCHEDULE 13D/A Tyra Biosciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
BetterLife Pharma closes $100M public offering on Canadian exchange
-
Lisata acquires Marea Therapeutics, raises $225M in private placement
-
Serapha Bio names Kenneth Mills as CEO, eyes Nasdaq listing
-
Tyra Biosciences prices $400 million stock offering at $22.03
-
Form SCHEDULE 13G JATT III Acquisition Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form N-PX RA CAPITAL MANAGEMENT, For: Jun 30
-
JATT III Acquisition Corp closes $69M IPO on Nasdaq
-
Court awards Biohaven and Yale $4M in trade secret case
-
Gossamer Bio raises up to $250M in private placement for PAH drug
-
Werewolf Therapeutics to merge with Ambros in $150M private placement
-
Form SCHEDULE 13G Latigo Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
-
Form SCHEDULE 13G/A GH Research PLC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Septerna, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Fulcrum Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Taysha Gene Therapies, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Rani Therapeutics Holdin Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Ovid Therapeutics Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A GERON CORP Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Edgewise Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Karyopharm Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A CervoMed Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A C4 Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A BIOCRYST PHARMACEUTICALS Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Atrium Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Avalo Therapeutics, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Adicet Bio, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G/A Aclaris Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form 13F-HR RA CAPITAL MANAGEMENT, For: Jun 30
-
Form SCHEDULE 13G TCGX Acquisition Corp. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Wave Life Sciences, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A SAB Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Obsidian Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G INOVIO PHARMACEUTICALS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G DBV Technologies S.A. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G Scribe Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G CAPRICOR THERAPEUTICS, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Obsidian Therapeutics completes Galera merger, raises $350M
-
Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Processa acquires Vidya Therapeutics in $200M private placement deal
-
Entera Bio prices $275M private placement led by BVF Partners
-
Entera Bio prices $275 million private placement led by BVF Partners
-
Jury awards Biohaven and Yale $4M in trade secret case
-
Form SCHEDULE 13D/A Artiva Biotherapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Freenome, Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13D/A Vor Biopharma Inc. Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SCHEDULE 13G AGENUS INC Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Freenome begins trading on Nasdaq after $310M SPAC merger
-
Form SCHEDULE 13G Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.

